Evotec SE
HealthcareNASDAQ:EVO · NASDAQ Global Select
+$0.00 today
Vol 0.01M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-12.2%
avg 1.6%
ROIC
-7.2%
avg 1.8%
ROA
-5.6%
avg 1.2%
Analysis
ROA is currently the strongest return metric at -5.6% versus its period average of 1.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christian Wojczewski | CEO & Chairperson of the Management Board | $2.88M | — | 53 | — | — |
Paul Hitchin | Chief Financial Officer & Member of Management Board | $1.34M | — | 50 | — | — |
Claire Hinshelwood | Chief Financial Officer & Member of Management Board | $1.34M | — | — | — | — |
Aurelie Dalbiez | Chief People Officer & Member of Management Board | $1.11M | — | 49 | — | — |
Cord Dohrmann | Chief Scientific Officer & Member of Management Board | $880,098.00 | — | 62 | — | — |
Ingrid Mller | Chief Operating Officer & Member of Management Board | $673,657.00 | — | 54 | — | — |
Ian Hunneyball | Senior Vice President of Programme Management & Clinical Operations | $133,803.00 | — | 76 | — | — |
Philip Boehme | Executive Vice President of Partnering & Transformation | — | — | — | — | — |
Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations | — | — | — | — | — |
Bernd Mühlenweg | Senior VP & Head of Global Business Development | — | — | — | — | — |
Uwe Andag | EVP Head of Metabolic Diseases | — | — | — | — | — |
Christiane Honisch | SVP Head of Diagnostics | — | — | — | — | — |
David Hallet | Executive Vice President | — | — | — | — | — |
Claudia Karnbach | Global Head & Executive VP of Partnering Excellence & Operations | — | — | — | — | — |
Guy Rachmuth | Senior VP of Global Strategic Business Development & Partnerships | — | — | — | — | — |
Christian Dargel | EVice President Global Head of Legal & Compliance | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +81.7% | +9.1% (15yr)1 analysts |
| Revenue | N/A | N/A | +13.5% | +14.6% (15yr)2 analysts |
| Net Income | N/A | N/A | +88.2% | +11.0% (15yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Net Income at +88.2% over three years. Forward estimates point to Revenue at +14.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Alvotech
NASDAQ:ALVO
$1.30B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Who manages EVO?
Evotec SE (EVO) lists 16 active executives. The top listed executive is Philip Boehme, Executive Vice President of Partnering & Transformation.
Are EVO insiders buying or selling?
Recent insider activity shows net buying of $1.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.